Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) PT at $6.67

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) have earned an average recommendation of “Moderate Buy” from the eight brokerages that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $8.1429.

A number of research firms have recently commented on CTMX. HC Wainwright raised their price objective on CytomX Therapeutics from $5.00 to $10.00 and gave the stock a “buy” rating in a report on Tuesday, November 11th. Barclays lifted their price target on shares of CytomX Therapeutics from $6.00 to $8.00 and gave the company an “overweight” rating in a research report on Tuesday, January 20th. Weiss Ratings raised shares of CytomX Therapeutics from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, October 8th. Wedbush restated an “outperform” rating and set a $6.00 target price on shares of CytomX Therapeutics in a report on Friday, November 7th. Finally, Piper Sandler upped their price target on shares of CytomX Therapeutics from $6.50 to $10.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 20th.

CytomX Therapeutics Stock Down 3.6%

NASDAQ:CTMX opened at $5.34 on Tuesday. The company has a market cap of $904.76 million, a P/E ratio of 13.35 and a beta of 2.42. The firm’s 50 day moving average is $4.30 and its two-hundred day moving average is $3.28. CytomX Therapeutics has a fifty-two week low of $0.40 and a fifty-two week high of $6.15.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings data on Thursday, November 6th. The biotechnology company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.05). The firm had revenue of $5.96 million for the quarter, compared to analyst estimates of $11.50 million. CytomX Therapeutics had a return on equity of 44.49% and a net margin of 24.66%. Research analysts forecast that CytomX Therapeutics will post -0.05 earnings per share for the current fiscal year.

Institutional Investors Weigh In On CytomX Therapeutics

Several hedge funds have recently modified their holdings of CTMX. Precision Wealth Strategies LLC purchased a new position in CytomX Therapeutics in the 3rd quarter worth approximately $756,000. Inspire Investing LLC purchased a new position in shares of CytomX Therapeutics in the third quarter valued at $1,667,000. Vivo Capital LLC acquired a new stake in CytomX Therapeutics during the 2nd quarter valued at $13,096,000. Franklin Resources Inc. purchased a new stake in CytomX Therapeutics during the 2nd quarter worth $13,096,000. Finally, Pursue Wealth Partners LLC acquired a new position in CytomX Therapeutics in the 2nd quarter worth $33,000. 67.77% of the stock is currently owned by hedge funds and other institutional investors.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.